血液透析時におけるAztreonamの臨床薬物動態の検討  [in Japanese] PHARMACOKINETICS OF AZTREONAM ON HEMODIALYSIS  [in Japanese]

Access this Article

Author(s)

Abstract

液透析患者6例にAztreonam (AZT) 1gをOnes hot静注し, 透析時及び非透析時の血清中濃度, 並びに透析性について検討した。<BR>血清中濃度は透析の影響を受け, 非透析時と透析時の比較では, 投与後1, 2, 6, 12時間値で有意差が認められ, 血清中濃度の半減期は16.97時間から3.44時間と短縮し, クリアランスは0.762L/hrから3.360L/hrと増加した。<BR>以上から, AZTを血液透析患者に投与するには投与量, 投与間隔を調整する必要があると考えられた。

We studied the pharmacokinetics of aztreonam (AZT) in 6 patients with renal insufficiencies during nonhemodialysis and hemodialysis.<BR>After intravenous injection of 1g AZT, it was found that serum AZT concentrations during, hemodialysis were different from those during nonhemodialysis and serum half-lives (T1/2β) were 3.44 hours and 16.97 hours, respectively. AZT clearance changed from 0.762L/hr during hemodialysis to 3.360L/hr during nonhemodialysis.<BR>These findings suggest that hemodialysis patients should receive the standard dose of AZT as a loading dose, followed by one-half the loading dose per day and receive a supplemental dose equal to half their usual maintenance dose after each dialysis session.

Journal

  • The Japanese Journal of Antibiotics

    The Japanese Journal of Antibiotics 43(2), 345-354, 1990

    Japan Antibiotics Research Association

Codes

Page Top